115 related articles for article (PubMed ID: 9795070)
1. Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy subjects.
Gasser UE; Crevoisier C; Ouwerkerk M; Lankhaar G; Dingemanse J
Eur J Pharm Biopharm; 1998 Sep; 46(2):223-8. PubMed ID: 9795070
[TBL] [Abstract][Full Text] [Related]
2. Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers.
Crevoisier C; Monreal A; Metzger B; Nilsen T
Eur Neurol; 2003; 49(1):39-44. PubMed ID: 12464717
[TBL] [Abstract][Full Text] [Related]
3. Effects of food on the pharmacokinetics of levodopa in a dual-release formulation.
Crevoisier C; Zerr P; Calvi-Gries F; Nilsen T
Eur J Pharm Biopharm; 2003 Jan; 55(1):71-6. PubMed ID: 12551706
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
[TBL] [Abstract][Full Text] [Related]
5. The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations.
Jorga K; Fotteler B; Schmitt M; Nielsen T; Zürcher G; Aitken J
Eur Neurol; 1997; 38(1):59-67. PubMed ID: 9252801
[TBL] [Abstract][Full Text] [Related]
6. Comparative bioavailability of 2 tablet formulations of levodopa/benserazide in healthy, fasting volunteers: a single-dose, randomized-sequence, open-label crossover study.
Keller GA; Czerniuk P; Bertuola R; Spatz JG; Assefi AR; Di Girolamo G
Clin Ther; 2011 Apr; 33(4):500-10. PubMed ID: 21635995
[TBL] [Abstract][Full Text] [Related]
7. Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers.
Crevoisier C; Hoevels B; Zürcher G; Da Prada M
Eur Neurol; 1987; 27 Suppl 1():36-46. PubMed ID: 3428308
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of levodopa/carbidopa microtablets versus levodopa/benserazide and levodopa/carbidopa in healthy volunteers.
Nyholm D; Lewander T; Gomes-Trolin C; Bäckström T; Panagiotidis G; Ehrnebo M; Nyström C; Aquilonius SM
Clin Neuropharmacol; 2012; 35(3):111-7. PubMed ID: 22549097
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
[TBL] [Abstract][Full Text] [Related]
10. Single-dose pharmacokinetics of Madopar HBS in patients and effect of food and antacid on the absorption of Madopar HBS in volunteers.
Malcolm SL; Allen JG; Bird H; Quinn NP; Marion MH; Marsden CD; O'Leary CG
Eur Neurol; 1987; 27 Suppl 1():28-35. PubMed ID: 3428307
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic studies with a dual-release formulation of levodopa, a novel principle in the treatment of Parkinson's disease.
Dingemanse J; Kleinbloesem CH; Crevoisier C; Lankhaar G; Gasser UE
Eur Neurol; 1998; 39(2):119-24. PubMed ID: 9520073
[TBL] [Abstract][Full Text] [Related]
12. Bioavailability and acceptability of a dispersible formulation of levodopa-benserazide in parkinsonian patients with and without dysphagia.
Bayer AJ; Day JJ; Finucane P; Pathy MS
J Clin Pharm Ther; 1988 Jun; 13(3):191-4. PubMed ID: 3209626
[TBL] [Abstract][Full Text] [Related]
13. COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa/benserazide. A novel principle in the treatment of Parkinson's disease.
Gasser UE; Jorga K; Crevoisier C; Hovens SE; van Giersbergen PL
Eur Neurol; 1999; 41(4):206-11. PubMed ID: 10343151
[TBL] [Abstract][Full Text] [Related]
14. Comparative multiple-dose pharmacokinetics of controlled-release levodopa products.
Grahnén A; Eckernäs SA; Collin C; Ling-Andersson A; Tiger G; Nilsson M
Eur Neurol; 1992; 32(6):343-8. PubMed ID: 1490503
[TBL] [Abstract][Full Text] [Related]
15. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
[TBL] [Abstract][Full Text] [Related]
16. Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics.
Rocha JF; Sicard É; Fauchoux N; Falcão A; Santos A; Loureiro AI; Pinto R; Bonifácio MJ; Nunes T; Almeida L; Soares-da-Silva P
Br J Clin Pharmacol; 2017 Mar; 83(3):540-553. PubMed ID: 27763682
[TBL] [Abstract][Full Text] [Related]
17. Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
Marion MH; Stocchi F; Malcolm SL; Quinn NP; Jenner P; Marsden CD
Eur Neurol; 1987; 27 Suppl 1():54-8. PubMed ID: 3322837
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
Yeh KC; August TF; Bush DF; Lasseter KC; Musson DG; Schwartz S; Smith ME; Titus DC
Neurology; 1989 Nov; 39(11 Suppl 2):25-38. PubMed ID: 2685649
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics.
Dingemanse J; Kleinbloesem CH; Zürcher G; Wood ND; Crevoisier C
Br J Clin Pharmacol; 1997 Jul; 44(1):41-8. PubMed ID: 9241095
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous quantitation of levodopa and 3-O-methyldopa in human plasma by HPLC-ESI-MS/MS: application for a pharmacokinetic study with a levodopa/benserazide formulation.
César Ida C; Byrro RM; Cardoso FF; Mundim IM; Teixeira Lde S; da Silva EP; Gomes SA; Bonfim RR; Pianetti GA
J Pharm Biomed Anal; 2011 Dec; 56(5):1094-100. PubMed ID: 21856105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
